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Abstract
Between 2005 and 2006, clinical specimens were collected from
31 infants with suspected congenital rubella syndrome (CRS)
who presented at six hospitals in Khartoum, Sudan. Eleven
(35.5%) were laboratory conﬁrmed as CRS cases by testing for
anti-rubella IgM, IgG and viral genome. For the ﬁrst time in
Sudan, the rubella virus genome was directly detected in clinical
specimens of six CRS cases and two viruses were isolated in cell
culture. Phylogenetic analysis suggested that three genotypes of
rubella virus (RV; 1E, 2B and 1G) were co-circulating in Sudan.
The study introduced the methodology for CRS conﬁrmation
and surveillance in Sudan and provides preliminary data.
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Surveillance for measles/rubella is conducted in Sudan, but
rubella vaccination is not included in the national immuniza-
tion programme. Rubella infection was found to be the most
frequent cause of non-measles rash in Khartoum [1]. In
1996, a sero-epidemiological study in Khartoum revealed
that 20.5% of the pregnant women were susceptible to
rubella [2]. However, no surveillance data for the congenital
rubella syndrome (CRS) are available in Sudan. This study
was conducted to provide information on the CRS burden
and characteristics of its causative agent, which may contrib-
ute to the establishment of CRS control strategies in Sudan.
Between June 2005 and May 2006, 31 infants under 1 year
of age who presented at six hospitals in Khartoum with sus-
pected CRS [3] were investigated, and 62 specimens includ-
ing 27 throat swabs (TS), ﬁve nasal swabs (NS), six oral
ﬂuids (OF) and 24 sera were collected. TS and NS were
placed in 2 mL of medium [4] and kept in liquid nitrogen.
OF were collected and extracted as previously described [5]
and kept at )20C, as were the sera, prior to testing [6].
Data on the clinical ﬁndings in the infants and the medical
history of the mothers were recorded (Table 1).
The study protocol was reviewed and approved by the
Ethical Review Committee, Federal Ministry of Health, Sudan.
Parents of infants meeting the CRS case deﬁnition were
informed about the study and consent was obtained before
enrolment.
Sera and OF were tested using a commercial ELISA
for rubella IgM (Microimmune Limited, Brentford, UK), and
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in-house capture ELISA for IgG as previously described [7].
From the 31 infants, 28 samples were collected for serologi-
cal testing (24 sera and four OF). In total, 8/28 (28.6%) were
IgM-positive and 20/28 (71.4%) were IgG-positive including
three infants (cases 3, 16 and 20) aged ‡6 months. As the per-
sistence of rubella IgG at ‡6 months of age, when the maternal
IgG normally disappears, is a marker for CRS diagnosis [8], and
their mothers had a history of rubella during the ﬁrst trimes-
ter, the three infants were also deﬁned as CRS cases. The eight
infants who were positive for rubella IgM were all £5 months
old. Of the 11 serologically conﬁrmed cases, eight (cases 3, 6,
16, 18, 19, 20, 21 and 29) were also clinically conﬁrmed
according to the WHO CRS case deﬁnition [3]. Clinical fea-
tures among the 11 cases included cataract (81.8%), cardiac
disease (72.7%), hepatosplenomegaly (54.5%) and microceph-
aly (27.3%) (Table 1).
Nine samples (ﬁve TS, three OF and one NS) collected
from seven infants (cases 6, 18, 19, 20, 21, 22 and 29) were
TABLE 1. Clinical picture and laboratory investigations of 31 infants suspected of CRS (conﬁrmed cases are shaded)
Case no.
Age
(Month)
Location
(state)
Clinical
picture IgM IgG
Virus
isolation
(IFAa)
Samples
for PCR
PCR E317/
E592
RV strain
name GBb.
Number
1c 2 Khartoum Cardiac Diseased, Microcephaly NTe NT NT TS
NS
)/NT
)/NT
2c 22 days Khartoum Cardiac disease ) + NT TS )/NT
3f, g 11 Khartoum Cardiac disease,
cataract, squint
) + NT TS )/NT
4c 5 White Nile Microcephaly, hepatomegaly,
mental retardation
) ) NT TS )/NT
5c 3 Gazeera Microcephaly, thrombocytopenia,
hepatosplenomegaly, prolonged jaundice
+ NT NT TS )/NT
6g 5 Khartoum Cardiac disease, cataract, squint, hepatomegaly,
meningo -encephalitis, microcephaly, hearing impairment
+ + ) TS )/NT
7c, g 2 Khartoum Meningoencephalitis, microcephaly, thrombocytopenia,
hepatosplenomegaly
) + NT TS
NS
)/NT
)/NT
8c,f 3 Khartoum Hepatosplenomegaly, prolonged jaundice ) + NT TS )/NT
9c 3 Khartoum Hepatosplenomegaly ) ) NT TS )/NT
10c,f 3 Khartoum Recurrent chest infection, failure to thrive,
low birth weight
) + NT TS )/NT
11c 8 Khartoum Microcephaly ) ) NT TS )/NT
12g 8 Khartoum Cardiac disease, cataract, microcephaly ) ) NT TS )/NT
13c 40 days Khartoum Hepatosplenomegaly, micro- pthalmia ) ) NT OF )/NT
14c 4 Khartoum Hepatosplenomegaly NT NT NT TS )/NT
15c 15 days Khartoum Microcephaly, hepatomegaly, jaundice
from the 1st day of birth
) + NT TS )/NT
16f, g 6 Khartoum PDAh, cataract, microcephaly, hepatomegaly,
hearing impairment
Eqvi + NT TS )/NT
17f, g 1 Khartoum Cataract and microcephaly ) + NT TS )/NT
18g 2 White Nile PDA, Microcephaly, hepatosplenomegaly,
blindness
+ + + TS +/+ RVi/Deweim.SDN/50.05[1G]
CRS FJ774999
19g 5 Khartoum VSDj, cataract, hepatomegaly + + ) TS
OF
)/NT
+/)
RVs/Khartoum.SDN/12.06[2B]
CRS FJ774995
20f, g 7 Khartoum Cardiac disease, cataract, micropthalmia,
microcephaly
) + ) TS
OF
)/NT
+/)
RVs/Khartoum.SDN/20.06[2B]
CRS FJ774996
21g 3 White Nile PDA, cataract and splenomegaly + + + TS
NS
)/NT
+/+
RVi/Deweim.SDN/24.05[1E]
CRS FJ775000
22c 2 Khartoum Cataract + + Discarded TS
NS
+/)
)/NT
RVs/Khartoum.SDN/49.05[1E]
CRS FJ774997
23c 6 White Nile Cataract NT NT NT TS
NS
)/NT
)/NT
24c 3 Khartoum Cataract + + NT OF )/NT
25g 1 Khartoum Cardiac disease, microcephaly ) + NT TS )/NT
26g 6 Khartoum Cardiac disease, microcephaly, hepatomegaly. ) ) NT TS )/NT
27g 3 Khartoum Microcephaly, hearing impairment ) ) NT TS )/NT
28c 4 Khartoum Hepatosplenomegaly and jaundice
from the 1st day of birth
) + NT TS )/NT
29f, g 40 day Gadarif VSD and cataract + + ) OF +/) RVs/Gadarif.SDN/22.06[2B]
CRS FJ774998
30c 5 days Khartoum Microcephaly, mental retardation,
meningoencephalitis
) + NT TS )/NT
31g 38 days Khartoum Cataract and hepatomegaly ) + NT OF )/NT
aIndirect immunoﬂuorescent.
bGenBank.
cSuspected CRS case.
dPositive clinical examination for cardiac congenital anomaly.
eNot tested.
fMaternal history of rubella during the ﬁrst trimester.
gClinically conﬁrmed CRS case. The shaded rows refer to laboratory-conﬁrmed cases.
hPatent ductus arteriosus.
iEquivocal.
jVentricular septal defect.
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Nucleotide substitutions 
RVi/Deweim.SDN/24.05[1E]CRS
RVs/Khartoum.SDN/49.05[1E]CRS
AY968210-1E
AY968214-1D
AY968216-1D
AY968221-1E
ab238919-1j 
AY968213-1F
AY968215-1F
AY968208-1B
am258953-1h 
DQ454161-1h
AM258945-1G 
EF210043-1G 
EF210044-1G
RVi/Deweim.SDN/50.05[1G]CRS
ay161352-1i 
ay161360-1i 
AY968207-1B
L78917 RA273-1a
AB047330-1a
Thoma-lab positive 
AY968209-1B
AY968211-1C
AY968212-1C
m30776-1a
af188704-1a
AY968217-1C
dq085340-2C
dq388279-2C
RVs/Khartoum.SDN/12.06[2B]CRS
RVs/Khartoum.SDN/20.06[2B]CRS
RVs/Gadarif.SDN/22.06[2B]CRS
AY968220 2B
AY968218 2B
AY968219 2B
AY258322-2A
AY258323-2A
2%
EF210046
EF210059-551nt
EF210045
EF210043
EF210044
EF588978-1G Uganda 01,
EF588979-1G Cote d’Ivoire 05
RVi/Deweim.SDN/50.05[1G]CRS 
EF588977-1G Uganda  07
AM258945-1G 
EF588970-1G
AM258953-1h 
DQ454161-1h
AY161352-1i 
AY161360-1i 
AY968208-1B
AY968209-1B
AY968207-1B
EF588971-601nt
EF588974-601nt
EF588972-601nt
EF588973-601nt
AY968210-1E
RVi/Deweim.SDN/24.05[1E]CRS
AY968221-1E
AY968216-1D
AY968214-1D
EF602117-1j 
AB238919-1j 
EF210060-Ethipoia 04-551nt
AY968213-1F
AY968215-1F
AB047330-1a
AF188704-1a
L78917 RA27 3-vacc
EF588976-601nt
EF588975-601nt
AY968220-2B
AY968218-2B
AY968219-2B
AY258323-2A
AY258322-2A
DQ085340-2C
DQ388279-2C
M30776-1a 
AY968217-1C
AY968212-1C
AY968211-1C
1E  
Morocco 02, 04  
1G 
Ethiopia 04 
2B 
S. Africa 02, 04
1%
(b)
(a)
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selected for rubella virus (RV) isolation according to the sero-
logical and PCR results. Specimens (200 lL) were inoculated
into Vero cells and cultured at 37C for 7 days, then frozen at
)70C until the next passage. The thawed mixture of cells and
supernatant was inoculated into fresh Vero cells for a further
7 days. Four passages were carried out and RV growth was
identiﬁed using an indirect immunoﬂuorescence assay [9] and
conﬁrmed by PCR. RV growth from two samples was con-
ﬁrmed, one TS (case 18) and one NS (case 21) (Table 1).
Total RNA was extracted from clinical samples and cell cul-
ture ﬂuid using the QIAamp Viral RNA Mini kit (QIAGEN,
Crawley, UK) according to the manufacturer’s instructions.
RNA was transcribed into cDNA as previously described [10].
Two assays, PCR-E317 [11] and PCR-E592 [12], were per-
formed, allowing ampliﬁcation of a 317 and a 592 nt region,
respectively, of the E1 gene, which together cover the 739 nt
window recommended by the WHO for genotyping [13].
Specimens from six (19.4%) of the 31 suspected CRS
cases, including two TS, three OF and one NS, were positive
by PCR-E317, whereas ﬁve were rubella IgM-positive (cases
18, 19, 21, 22 and 29) and one was IgG-positive (case 20).
Rubella RNA was not detected in any IgM-negative case. The
results showed that PCR-E317 was more sensitive than
PCR-E592 [11] where only two samples (TS of case 18 and
NS of case 21) were positive among six PCR-E317-positive
samples which were also the two samples positive by RV iso-
lation. RV is labile, and may lose its integrity and suffer a
decrease in viral load in samples collected during ﬁeld inves-
tigations when samples are subjected to cycles of freeze–
thawing [14], which may explain the negative PCR results
obtained in IgM-positive CRS cases. Otherwise, RV secretion
is detectable up to 7 months after birth (case 20).
PCR products were puriﬁed using QIAquick Spin columns
(QIAGEN) and sequenced as previously described [15].
Genotype designation was based on sequence comparisons
with WHO reference strains. Phylogenetic analysis of the six
RV strains based on the 280 nt amplicon (excluding the pri-
mer sequences) of the E1 gene generated by PCR-E317
showed that three genotypes, 1E, 2B and 1G, were co-circu-
lating in three Sudanese states according to the birth place
of the infants during 2005–2006 (Fig. 1a). The two genotype
1E strains were 100% identical and were detected in Khar-
toum and the White Nile states. The three 2B strains, two
found in Khartoum and one in Gadarif, were 100% identical.
The only genotype 1G was detected in the White Nile
states. Strains were named according to the WHO nomen-
clature for RV [13].
A phylogenetic tree (Fig. 1b), based on the window of 739
nt [13,16], was constructed for the two isolates RVi/Dew-
eim.SDN/50.05[1G]CRS and RVi/Deweim.SDN/24.05[1E]CRS
from cases 18 and 21, which contributed to an overview of
RV genotype distribution in Africa and to the tracking of
possible RV transmission links in Sudan. In addition to those
of the WHO reference strains, all sequences of RV detected
in Africa were analysed. During 2004–2007, the genotype 1G
was also detected in Ethiopia, Uganda and Cote d’Ivoire
[11,17], and 1E in Morocco during 2002–2004 [17], but none
of these were identical to the 1G and 1E strains found in
Sudan in 2005 although the divergence was small. During
2002–2004, the genotype 2B was found in South Africa, but
there are no available data for comparison with the 2B
strains found in Sudan.
This is the ﬁrst report of a CRS investigation and molecu-
lar characterization of RV detected in Sudan. Thirty-ﬁve per
cent of suspected CRS were a result of RV infection. OF
sampling could be the best choice for CRS conﬁrmation in
the future because of its expediency and suitability for both
serological and molecular testing (a suggestion made despite
the small number of samples analysed in this study).
The baseline information generated in this study contrib-
uted to CRS surveillance in Sudan and informed Sudanese
government decisions in developing rubella vaccination
policy.
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